A number of other research firms have also recently issued reports on COLL. Cantor Fitzgerald reaffirmed an overweight rating and issued a $24.00 price target (down previously from $35.00) on shares of Collegium Pharmaceutical in a report on Thursday, August 8th. Zacks Investment Research raised shares of Collegium Pharmaceutical from a sell rating to a hold rating in a report on Thursday, August 8th. ValuEngine raised shares of Collegium Pharmaceutical from a sell rating to a hold rating in a report on Thursday, August 1st. Finally, HC Wainwright initiated coverage on shares of Collegium Pharmaceutical in a report on Friday, May 3rd. They set a buy rating and a $23.00 target price for the company. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $24.33.
NASDAQ COLL opened at $11.52 on Tuesday. The company has a fifty day simple moving average of $11.43 and a two-hundred day simple moving average of $13.70. The stock has a market cap of $370.21 million, a P/E ratio of -9.68 and a beta of 0.54. Collegium Pharmaceutical has a 12-month low of $10.01 and a 12-month high of $19.83. The company has a current ratio of 1.25, a quick ratio of 1.20 and a debt-to-equity ratio of 0.23.
In related news, CEO Joseph Ciaffoni sold 7,436 shares of the firm’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $11.59, for a total transaction of $86,183.24. Following the completion of the transaction, the chief executive officer now owns 190,755 shares of the company’s stock, valued at $2,210,850.45. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Michael Thomas Heffernan sold 25,000 shares of the firm’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $11.26, for a total transaction of $281,500.00. Following the transaction, the director now directly owns 132,069 shares of the company’s stock, valued at approximately $1,487,096.94. The disclosure for this sale can be found here. In the last three months, insiders have sold 66,144 shares of company stock valued at $754,506. 8.08% of the stock is currently owned by corporate insiders.
Hedge funds have recently added to or reduced their stakes in the stock. MERIAN GLOBAL INVESTORS UK Ltd acquired a new stake in Collegium Pharmaceutical during the first quarter valued at $26,000. First Quadrant L P CA acquired a new stake in Collegium Pharmaceutical during the first quarter valued at $36,000. BNP Paribas Arbitrage SA grew its position in Collegium Pharmaceutical by 67,855.6% during the first quarter. BNP Paribas Arbitrage SA now owns 6,116 shares of the specialty pharmaceutical company’s stock valued at $93,000 after buying an additional 6,107 shares during the period. Paradigm Capital Management Inc. NY acquired a new stake in Collegium Pharmaceutical during the second quarter valued at $131,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Collegium Pharmaceutical during the second quarter valued at $137,000. Institutional investors own 96.29% of the company’s stock.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.